GPCR allosteric modulators target at the allosteric binding pockets of G proteincoupled receptors (GPCRs) with indirect influence on the effects of an orthosteric ligand. Such modulators exhibit significant advantages compared to the corresponding orthosteric ligands, including better chemical tractability or physicochemical properties, improved selectivity, and reduced risk of oversensitization towards their receptors. Metabotropic glutamate receptor 5 (mGlu 5 ), a member of class C GPCRs, is a promising therapeutic target for treating many central nervous system diseases. The crystal structure of mGlu 5 in the complex with the negative allosteric modulator mavoglurant was recently reported, providing a fundamental model for designing new allosteric modulators. Computational fragment-based drug discovery represents a powerful scaffold-hopping and lead structure-optimization tool for drug design. In the present work, a set of integrated computational methodologies was first used, such as fragment library generation and retrosynthetic combinatorial analysis procedure (RECAP) for novel compound generation. Then, the compounds generated were assessed by benchmark dataset verification, docking studies, and QSAR model simulation. Subsequently, structurally diverse compounds, with reported or unreported scaffolds, can be observed from top 20 in silico synthesized compounds, which were predicted to be potential mGlu 5 modulators. In silico compounds with reported scaffolds may fill SAR holes in known, patented series of mGlu 5 modulators. And the generation of compounds without reported tests on mGluR indicates that our approach is doable for exploring and designing novel compounds. Our case study of designing allosteric modulators on mGlu 5 demonstrated that the established computational fragment-based approach is a useful methodology for facilitating new compound design in the future.
INTRODUCTION
The human G protein-coupled receptors (GPCRs), which can also be described as seven-transmembrane (TM) receptors account for more than 1% of human genome. The GPCR superfamily, comprised more than 800 receptors, can be further categorized into four different classes, classes A, B, C, and F (Frizzled), according to their sequence homology (1, 2) . As essential receptors associated with a variety of physiological processes, including neurotransmission, immune defense, and cell growth, over 30% of currently marketed drugs are using GPCRs as their targets (3, 4) .
Each GPCR possesses an orthosteric binding pocket for its respective endogenous ligands. Compounds derived from natural sources or chemical synthesis binding to this pocket are termed orthosteric ligands (5) . Early drug development was focused on the orthosteric modulation and almost all of the FDA-approved compounds for therapeutic use target at the orthosteric binding sites of the receptors (5, 6) . However, the ligands coming out from this strategy have drawbacks including Yuemin Bian and Zhiwei Feng contributed equally to this work.
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The online version of this article (doi:10.1208/s12248-017-0093-5) contains supplementary material, which is available to authorized users. limited or poor selectivity, a lack of efficacy, and resistance or decreased efficacy upon chronic administration (7) (8) (9) . GPCRs can have allosteric binding sites, which have topological and functional distinctions from corresponding orthosteric binding sites. The existence of allosteric binding pockets allows additional interactions between ligands and receptors (5, 10, 11) . Across a receptor family, the allosteric pockets usually stand with less evolutionary pressure for conservation, and the corresponding allosteric ligands usually have better selectivity. Meanwhile, allosteric ligands have a ceiling effect, which means their effects are saturable (12, 13) . Based on the modes of pharmacology, allosteric ligands can be categorized into positive allosteric modulators (PAMs), which enhance agonist-mediated receptor response, negative allosteric modulators (NAMs), which noncompetitively attenuate orthosteric activities, and silent allosteric modulators (SAMs), which have no effect on responses triggered by orthosteric ligands but block the effects caused by PAMs and NAMs (5) . The clinical success of the benzodiazepines attracts the attention of using allosteric regulation as a promising therapeutic strategy (14) .
Metabotropic glutamate receptor 5 (mGlu 5 ) is a member of class C GPCRs, which mainly responds to glutamate, one of the major neurotransmitters (15) . Class C GPCRs include metabotropic glutamate receptors, taste receptors, calcium-sensing receptors, GABA B , and others. mGlu 5 is a promising drug target for the treatment of diseases ranging from fragile X syndrome to depression and movement disorder (16) . mGlu 5 -negative allosteric modulators, which could attenuate orthosteric ligands mediated mGlu 5 activation, are under clinical evaluation for the treatment of multiple diseases (17, 18) . Dr. Fiona H. Marshall and her group have reported the crystal structure of the transmembrane domain of human mGlu 5 receptor, in the complex with mavoglurant, the negative allosteric modulator. The structure provides the precise location of the allosteric binding site within the transmembrane domain (16) . Multiple research groups have focused on the allosteric regulation of mGlu 5 , for example, Andreas Ritzen's group and P. Jefferey Conn's group designed and synthesized a series of allosteric ligands for mGlu 5 (19) . Although a classical structure-based medicinal chemistry approach could be useful for the generation of corresponding allosteric modulators, state-of-the-art computational methods could also be powerful tools in generating new ideas in allosteric modulator design in this field (20, 21) .
Fragment-based approaches for designing and generating lead compounds have proven quite fruitful in drug discovery. There are several ways that fragment-based approach could be applied to drug discovery: (1) binding sites and pharmacophores identification for receptor binding could be achieved with fragment screening techniques; (2) HTS libraries could be biased and the optimization of lead compounds could be guided with fragments screening hits; (3) leads with the potential to be optimized into drug-like compounds can be identified with fragment screening (21) (22) (23) (24) (25) . Fragment binding can reveal hot spots on proteins, which could result in high-affinity receptor-ligand interactions. The fragment-based approach is especially suitable for detecting the interaction spots among the protein-ligand binding, as fragments are capable of forming relatively strong interaction with a certain region of the target protein. Once the identification of fragments inside the binding pocket is done, these fragments could be grown, linked, or merged to develop the potential ligands (21) . A number of fragment-based screening campaigns have successfully delivered clinical candidates (26) . Steven Howard and his group successfully applied fragment-based screening and fragments linking to discover novel thrombin inhibitors (27) . Philip D. Edwards and his group reported the novel cyclic amidine β-secretase with the fragment-based approach to generate lead compounds (28) . However, there are still several undesired drawbacks for this approach. The defects of the experimental fragment-based method include time consuming, costly, and low affinity of hits (21, 29, 30) . Another complementary way to approach fragment-based drug discovery is the application of computational methods, which can offer several advantages: (1) computational methodologies can construct high-quality and diversified fragment libraries with both time and cost efficiencies (31, 32) ; (2) computational approaches can easily explore larger fragment databases; (3) optimization strategies for improving the drug-likeness of the hits with computational tools have efficiency and flexibility (33) . Recently, a drug design effort, which involved virtual screening of a fragments library, binding confirmation by NMR, X-ray crystallography, and structure-based optimization of fragments, by a research group in AstraZeneca, led to the discovery of highly potent FXIa inhibitors (34) . Another example is the development of inhibitors of cyclophilin A. Li's group reported that amide fragment, which functions as the key linker, is one of the critical pharmacophores for CypA inhibitors (35) . Through computational FBDD approaches, acylurea was designed by fusing amide and urea to function as a new linker and contributed to the discovery of novel inhibitors.
In our in silico research, we used a computational fragmentbased approach to propose structures as potential novel allosteric modulators of mGlu 5 . We generated a fragment library according to the reported GPCRs' allosteric modulators on Allosteric Database (ASD v2.0) (36) . Retrosynthetic combinatorial analysis procedure (RECAP) analysis and synthesis were used to generate the novel compounds. Molecular docking was applied to screen the hits for mGlu 5 by docking the in silico synthesis compounds back to the pocket with predicted binding energy and docking scores. Multiple computational methodologies, including benchmark dataset verification, docking studies, QuaSAR model, etc. were utilized for further validation of our hits. Twenty in silico synthesized compounds are predicted to be potential mGlu 5 allosteric modulators with preferable binding energies and docking scores. Structure diversity among the in silico design could be observed. Series of compounds with reported allosteric activities on mGluR could be recurred. Our case study on designing allosteric modulators on mGlu 5 suggested that this computational fragment-based approach is a useful methodology for facilitating the future compound design processes.
MATERIALS AND METHODS

X-ray Structures and GPCR Allosteric Modulators
Two crystal structures of the transmembrane domain of the human mGlu 5 were used in this work. The first model (PDB entry: 4OO9; resolution, 2.6 Å; method, X-ray diffraction) (16) was in complex with the negative allosteric modulator, mavoglurant. The second model (PDB entry: 5CGD; resolution, 2.6 Å; method, X-ray diffraction) (37) was in complex with the negative allosteric modulator, HTL14242. The structures of mGlu 5 were downloaded from the Protein Data Bank (PDB). Then, the SYBYL-X 1.3 (38) was used for the preparation of the crystal structure, including energy minimization and residue repair (39) .
Ligands were downloaded from the Allosteric Database (ASD v2.0) (36) . SYBYL-X 1.3 and PyMol (http:// www.pymol.org) were used for molecular visualization, structural superimposition, and data analysis (40) .
Fragment Generation and In Silico Synthesis
RECAP Analysis and RECAP Synthesis in ChemAxon's Fragmenter (https://www.chemaxon.com) were applied to generate our fragment library. The purpose of RECAP analysis is to fragment compounds according to simple retrosynthetic analysis rules and gather statistics towards fragment products. The RECAP synthesis could be applied to combine fragment products from RECAP analysis randomly, in order to produce the novel chemical structures, which should be synthetically reasonable (41, 42) . RECAP analysis was used for the establishment of the fragment library from allosteric modulators. And RECAP synthesis was used for the generation of in silico synthesized novel structures from processed, analyzed, and categorized fragments. The molecule filter was set to be leadlike (43) . The heavy atoms were set to be 25 in average with 11 in standard deviation.
Molecular Docking for the Studies of mGlu 5 -Ligand Interactions
We performed the molecular docking between crystal structure of mGlu 5 and fragments in the fragment library using SYBYL-X 1.3. Surflex-Dock GeomX, the docking algorithm that implemented in SYBYL, was applied to predict detailed receptor-ligand interaction. The total score was expressed as −log 10 (K d ) (44) . In the docking simulations, the allosteric binding site was first defined to cover all residues within 4 Å of the NAM in the initial mGlu 5 -mavoglurant complex. The Kollman all-atom approach was used to calculate atomic charges for the protein (45) and the Gasteiger-Hückel approach for the ligand (46) . The movement of hydrogen atoms of the protein was allowed. Additional starting conformations per molecule were set to 10, and the angstroms to expand search grid was set to 6. Three independent runs were performed for our fragment library.
Molecular docking between the in silico synthesized compounds and mGlu 5 was done with SYBYL-X 1.3 and (48) , was used in this study. The grid box contained the entire allosteric binding site of the mGlu 5 and permits translation and rotation of ligands. Numbers of points in grid box for three dimensions were 24, 24, and 22; spacing (angstrom) was 1.000. AutoGrid has been used for calculating the energy map of each atom in the ligands. The receptor was set to be rigid. Genetic algorithm with default parameters was chosen for the search. A binding energy, which is constituted by intermolecular energy, internal energy, torsional energy, and unbound extended energy, was reported for each run.
Generation of Benchmarking Dataset
A key metric for docking studies of molecules remains the enrichment of top hits (49) . Once a docking screening could distinguish active compounds as top hits against a large number of decoys in the database, this docking screening is considered a success (50) . In order to distinguish the in silico synthesized compounds from decoys in the docking processes, a benchmarking dataset is introduced. In the spirit of the DUD (49) and DUD-E (51) reference data sets for validation studies, 50 decoys, which have similar physical properties but distinctive topological properties with the reported mGlu 5 NAM, were generated through http://decoys.docking.org, using the reported protocols and parameters.
Quantitative Structure-Activity Relationship Model
The correlation between the structures of molecules and their corresponding chemical or physical properties could be summarized and predicted with quantitative structure-activity relationships (QSAR) techniques (52) . A QSAR model could be used to evaluate specific parameters that affect some properties of the molecules or to estimate same properties for other molecules in the same series (53) . A QSAR model, dealing with the correlation between the LogKi value and theoretical descriptors for molecules, was developed for a set of 1,2-diphenylethyne mGlu 5 NAMs. Sixty-six analogs of 1,2-diphenylethyne with existing Ki values were acquired from ASD. Ki values underwent logarithmic transformation to get LogKi values. Kennard-Stones algorithm was used for determining the training and test sets. One hundred eightysix descriptors were added towards each compound. Four criteria, contingency coefficient, Cramer's V, entropic uncertainty, and linear correlation, were used to evaluate the Fig. 1 . Allosteric binding site of mGlu 5 . a The allosteric binding site (highlighted in salmon pink), which is formed by surrounding residues, marked in cyan. b The interaction between mavoglurant and surrounding residues based on the spatial information from the reported crystal complex. c Docking pose and ligand-residue interaction predicted through the docking study. d The overlap of mavoglurant between crystallized complex and predicted pose contribution of each descriptor after the contingency analysis (54) (55) (56) . Partial least squares (PLS) regression method was used for building the model with selected descriptors. The model has been verified with the test set and used for the prediction of in silico synthesized compounds.
RESULTS
The Establishment of Fragment Library
Twenty-seven thousand two hundred sixty-two GPCR allosteric modulators were downloaded from ASD. RECAP analysis in ChemAxon's Fragmenter (https://www.chemaxon.com) was used to generate our fragment library. "Rule of three" (57, 58) rather than "rule of five" (59) was used here for guiding the selection of ideal fragments according to the recent reports. The contents for "rule of three" included molecular weight <300, hydrogen bond donors ≤3, hydrogen bond acceptors ≤3, and cLogP ≤3. After deleting duplicated items, a library with 863 fragments was generated. Among them, 47 fragments had their molecular weights over 300, 3 fragments had over 3 hydrogen bond donors, 56 fragments had over 3 hydrogen bond acceptors, and 72 fragments had their LogP(o/w) values over 3. Table I demonstrates top ten most frequently appeared fragments with corresponding properties as an example. A comparison between the fragment library we generated and the Maybridge fragment library was conducted. MACCS structural keys were used for calculating the fingerprint of each fragment. Tanimoto coefficient was set to be 80%. Seventy-eight percent of fragments in the library we generated could be matched with items in Maybridge library, while the remaining 22% of fragments may contribute to the particularity of GPCR allosteric modulators.
Docking Studies of Fragments into mGlu 5
Before the docking studies of the fragments library we generated, we first docked the reported NAM, mavoglurant, back to the defined allosteric binding site to function as a control for the validation of our docking process. Residues from TM2, TM3, TM5, TM6, and TM7 formed the pocket. Gly624, Ile625, Gly628, Pro655, Ser805, Val806, and Ser809 were directly involved in the pocket (Fig. 1a) . Comparing our docking results with the crystal structure of human mGlu 5 (PDB entry: 4OO9; resolution, 2.6 Å; method, X-ray diffraction) (16) in complex with the negative allosteric modulator, mavoglurant bound well inside the pocket with the alkyne linker traversing a narrow channel between Tyr659, Ser809, Val806, and Pro655. Three hydrogen bonds could be formed between mavoglurant and Asn747, Ser805, and Ser809 (Fig. 1b) . Our docking studies between mavoglurant and the defined allosteric binding site provided congruent results with the crystal structure. Identical residues were involved in the formation of hydrogen bond (Fig. 1c) . The docking result overlapped well with the crystallized complex, with the RMSD of ∼0.3 Å (Fig. 1d) , indicating that our docking process is relatively reliable.
Then, the generated fragments in our fragment library were docked into the mGlu 5 allosteric binding site. We conducted three independent docking studies for all fragments and found that fragments invariably aggregated into two distinct regions of the binding pocket of mGlu 5 , an upper region and a bottom region (Fig. 2a, b) . The number of fragments for each region is summarized in Fig. 2c . Our docking results were very consistent across our three independent runs, with ∼416 (85%) of fragments in the upper region and ∼320 (87%) of fragments in the bottom region were repeated in the same region throughout the three docking runs.
In Silico Synthesis of Novel Compounds from Categorized Fragments
A single fragment may bind with low affinity to a protein because of the lower molecular weight, which results in a limited amount of ligand-receptor interaction (60) . The combination of the fragments from upper and bottom regions is a promising strategy for increasing the affinity of binding. RECAP synthesis in ChemAxon Fragmenter was used to combine the fragments in upper region with the fragments in the bottom region. To find out whether the docking scores can be used as guidance for RECAP Synthesis, a trial was first conducted. A small scale of RECAP synthesis was performed with two sets of fragments: (1) ∼600 compounds were generated by 30 fragments in upper region and 20 in bottom region with the highest docking scores; (2) ∼600 compounds were generated by 30 fragments in upper region and 20 in bottom region with the lowest docking scores, respectively. The distribution of their docking scores (Fig. 3a) revealed that the combination of fragments with higher docking scores tended to result in compounds with better binding affinities. The MannWhitney test showed that asymptotic significance (two-tailed) is less than 0.001, which meant that these two distributions were significantly different. Then, 9600 novel compounds were generated through the large-scale RECAP synthesis with 120 highest scored fragments in the upper region (Supplementary Table 1 ) and 80 highest scored fragments in the bottom region (Supplementary Table 2 ). Our results showed that 124 in silico synthesized compounds had the docking score higher than seven (Supplementary Table 3 ). Since the docking score was expressed as −log10(Kd), as described in "Materials and Methods", compound with a docking score higher than 7 means that its corresponding predicted Kd is less than 10 −7 Mol, which is a positive sign for binding affinity. Interestingly, six in silico synthesized compounds have higher Table II . Moreover, we introduced binding energy of molecular docking as a supplementary evidence for receptor-ligand interaction by using AutoDock 4.0. The results of top 20 compounds can be found in Table II . A correlation plot was drafted (Fig. 4) to show the relationship between the docking score and the binding energy for each compound. All of these 20 in silico synthesized compounds had a predicted negative binding energy, which had a high correlation with the docking scores (61, 62) , providing the evidence that the docking studies with SYBYL-X 1.3 and AutoDock 4.0 were consistent with each other.
The binding poses of the highest ranked in silico synthesized compound was compared with the reported NAM, mavoglurant. The in silico synthesized compound occupied the identical position as mavoglurant (Fig. 1b) , forming the hydrogen bond with Ser805 (Fig. 3b) . Two compounds overlapped very well with the RMSD of 1 Å, as shown in Fig. 3c . Interestingly, our docking studies suggest that compound 1, our highest scoring compound proposed by our in silico methods, is predicted to form hydrogen bonds with Thr735 and Tyr659, which are not reported for mavoglurant. These two additional receptor-ligand interactions might explain the higher docking score acquired by the highest ranked in silico synthesized compound than mavoglurant. Whether these would form if compound 1 were synthesized and crystallization attempted would be an interesting experiment to conduct.
Evaluation of Docking Process and In Silico Synthesized Compounds with a Benchmarking Dataset
Dr. John. J. Irwin and his group generated the Directory of Useful Decoys, Enhanced (DUD-E), which is available at http://dude.docking.org. The physical properties used are molecular weight, calculated LogP, H-bond donors and acceptors, the number of rotatable bonds and net molecular charge in order to build physically similar decoys (51) . A tool (http://decoys.docking.org), which is automated and available online, could be used for generating the matched decoys for user-supplied ligands. The reported mGlu 5 NAM, mavoglurant, was used as the ligand for decoys generation. seventy-one compounds, including 50 decoys (Supplementary  Table 4) , mavoglurant, as well as top 20 in silico synthesized compounds were docked into mGlu 5 (Fig. 5) . Our results showed a clear enrichment of NAM and in silico synthesized compounds against 50 decoys. These results indicated that 20 in silico synthesized compounds could be enriched with NAM and were different from challenging decoys.
Prediction of Competition Binding with a Quantitative Structure-Activity Relationship Model
The selectivity of a ligand towards receptor subtypes could be measured with the competitive binding assay, which also reveals the percentage and density of each subtype among a certain tissue (63) . Competition binding is widely used in testing potential allosteric modulators for GPCRs. Sixty-six analogs of 1,2-diphenylethyne with existing Ki values were selected from ASD (Supplementary Table 5 ). Table II were tested by "Pan Assay Interference Compounds" (PAINS, www.cbligands.org/PAINS/), and all compounds passed the filter. Toxtree (http://toxtree.sourceforge.net/index.html) is a software to estimate the toxic hazard through decision tree approach (66) . All these top 20 in silico synthesized compounds were tested with Toxtree, and all of them had the same level of estimated toxic hazard with the reported NAM, mavoglurant.
The Effects on Ligand and Fragment Binding Caused by the Rotation of Trp785
The Trp785 on TM6 is highly conserved, which is similar to the central toggle switch in class A GPCRs. The different conformations of Trp785 could be observed between different crystal models due to the cocrystallization with different chemotypes. John A. Christopher and his group cocrystallized the mGlu 5 with HTL14242 and another molecule in the series in 2015. Their crystal model of mGlu 5 (PDB entry: 5CGD) has a different Trp785 conformation (Fig. 7a, b) . The evaluation of ligand and fragment binding between these two models were performed to illustrate the effects caused by the rotation of a critical residue Trp785. Trp785 rotates out of the allosteric binding pocket on 4OO9, which results in a relatively large pocket, especially for the upper region (Fig. 7a) . While for 5CGD, the Trp785 rotates into the allosteric binding pocket, which narrows down the space inside. One hydrogen bond could be formed between Trp785 and Ser809 in 5CGD, which further limits the size of the substructures for ligands to the top (Fig. 7b) . The docking study between the mavoglurant and 5CGD showed that the saturated bicyclic ring system was no longer favored in the upper region due to the severe collision with Trp785. Instead, the aromatic ring on mavoglurant was placed in the upper region with potential hydrophobic interactions with rings system on Trp785, and the saturated bicyclic ring system was placed in the bottom region (Fig. 7c, d ). This pose of mavoglurant was not favored by the allosteric binding pocket with a docking score of 4.5. The docking studies between 5CGD and 80 highest scored fragments in the bottom region, as well as 120 highest scored fragments in upper region were followed. The aggregation of fragments in the bottom region remained relatively well. Figure 7e shows that the rotation of Trp785 has limited influence on the fragment aggregation in the bottom region. Although some big fragments may invade into the upper region, the same situations could be observed with 4OO9, because of the size of these big fragments. Figure 7f shows that the aggregation of fragments in the upper region can no longer been maintained, especially for big fragments. The fragments that used to be categorized in the upper region tend to distribute among both upper and bottom regions in 5CGD. The distribution of fragments (Fig. 7g) showed that the bottom region is favored by the majority of the fragments. Although the overall properties of the upper region remain hydrophobic, the rotation of Trp785 significantly affects the shape of the upper region. The dramatic conformational changes on critical residues would have unignorable effects towards the effectiveness of the computational fragment linking described in this paper. Fragment growth and fragment merge would be alternative methodologies for novel compound generation using the model 5CGD. Based on the identified fragment hits, linkers and functional groups can be introduced to improve the chemical physical properties and drug likability. These works may be beyond the scope of this paper, and 4OO9 was focused to illustrate the study approach.
DISCUSSION
According to the primary principle of Medicinal Chemistry, similar compounds can have similar bioactivities. In order to further validate our in silico synthesized compounds, we tried to find out whether there are existing mGlu 5 allosteric modulators that are structurally similar to our in silico synthesized compounds.
A similarity search was performed on SciFinder (scifinder.cas.org) using compound 1, which is the most potent one according to our prediction, as listed on Table II . The search was started with chemical structures and the search type was similarity. The hits with Tanimoto coefficients over 85% were selected for further analysis. Interestingly, we identified one compound (CAS number 1197356-89-0), which is 90% similar towards compound 1, to be almost identical towards compound 6 (97%) listed on Table II. The only difference between 1197356-89-0 and compound 6 is the substitution on the benzene ring (Fig. 8a) , with compound 6 featuring chlorine substitution instead of a fluorine. Compound 1197356-89-0 was first published on a US patent, Piperazine Metabotropic Glutamate Receptor Negative Allosteric Modulators for Anxiety/Depression, US 2009/0325964 A1. A competitive binding assay, which assesses compounds' ability to displace MPEP from Hek-293 cell membrane expressing rat mGlu 5 receptors, was used to identify the compounds' activity in that patent (67) . Median Ki value for 1197356-89-0 is 20 nM (LogKi = 1.30), while our prediction for compound 6 is 324.2 nM (LogKi = 2.51). Since logarithmic transformation was used in our QSAR model simulation, the difference in absolute Ki value is reasonable and acceptable. The promising biological activity of 1197356-89-0 demonstrates that our method for in silico design can identify promising chemotypes for targets of interest when an existing crystal structure is available to build a model around. We further assessed whether the difference between the chlorine and fluorine would be the key component for the activity. It is known that fluorine could function as a hydrogen bond acceptor to intermediate receptor-ligand interactions. But, for chlorine, there is almost no reported role in hydrogen bond interactions. Another compound in that patent, 1197358-18-1, has chlorine connected towards the benzene ring (Fig. 8a) . The major difference between 1197358-18-1 and 1197356-89-0 is the substitution on the piperazine ring. For 1197358-18-1, a pyridine is attached, while for 1197356-89-0, a pyrimidine is attached. Median Ki value for 1197358-18-1 is 3 nM (LogKi = 0.48), which shows that the change from fluorine to chlorine does not decrease the allosteric regulation potency. Among our in silico synthesized compounds, with an additional methyl group on pyridine, compound 7 listed on Table II shares 96% similarity towards 1197358-18-1 (Fig. 8a) . The predicted Ki value for compound 7 is 545.0 nM (LogKi = 2.73). So, the potency of 1197358-18-1 turns out to be another evidence to support our in silico design. And the consistency between predicted Ki value and experimental data shows our evaluation is reliable to some extent. Through searching the original allosteric modulator database, which used for our fragments generation, there are no identical structures to these two compounds in patent. Although similar compounds do exist, they share a low Tanimoto coefficient.
Meanwhile, since compounds 10, 13-16, and 18 have distinctive structures to 1,2-diphenylethyne analogs and piperazine scaffold described in the abovementioned patient, similarity searches for them on Scifinder were continued. Compound 1312414-34-8, which shares 93% similarity with compound 10, is a compound that published on a US patent, Bicyclic Thiazoles as Allosteric Modulators of Mglur5 Receptors, US 2012/0258955 A1 (68) . Compound 1312414-34-8 was tested with functional assay, and the pEC 50 value is 5.29. Compound 10 has one additional methoxy group connected with the aromatic ring, when compared with 1312414-34-8 (Fig. 8b) . Compound 879873-30-0 is a compound that is included on a US patent, Novel Thieno-Pyridine and Thieno-Pyrimidine Derivatives and Their Use as Positive Allosteric Modulators of Mglur2-Receptors, US 20070275984 A1 (69) . Compound 879873-30-0 shares 97% similarity towards compound 14. Compound 14 has one additional methyl group connected with alkane chain (Fig. 8c) (Fig. 8d ) (70) . The EC 50 (nM) for 1276013-84-3 recorded on the patent is 120. Compound 19 shares same 3-cyano-pyridone scaffold with 950199-70-9 with an 83% similarity (Fig. 8e) . Compound 950199-70-9 is listed on a US patent, 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors, US 2014/0315903 A1 (71) . The pEC 50 of 950199-70-9 for the GTPγS-PAM is 6.7. For compound 13, it shares 83% similarity with 36295-38-2 (Fig. 8f) . Dr. Rosaria Gitto's group reported that N-substituted isoquinoline derivatives could be functioned as potential AChE inhibitors. But, there are no reported activities on metabotropic glutamate receptors for Nsubstituted isoquinoline derivatives, as 36295-38-2.
The recall of compounds with existing scaffolds and reported effects on mGluR showed that the approach we generated is feasible. And the discovery of compounds with unreported activities on mGluR revealed that our approach is doable for exploring and designing novel compounds.
CONCLUSION
In this study, we demonstrated a case study of designing allosteric modulators on metabotropic glutamate receptor 5 using in silico fragment-based novel compound design. A GPCR allosteric modulator specific fragment library was generated, which could be used for future studies. Various computational methodologies, including benchmarking dataset validation, docking studies, QuaSAR model simulation, etc., were used to construct the in silico compounds and validate the effectiveness of this lead generation strategy. The effects associated with the rotation of toggle switch, Trp785, were considered and evaluated. The dramatic conformational changes on critical residues would have unignorable effects towards the effectiveness of the computational methodology described in this paper. The determination of using one model or combining two or more models should be specified at the beginning of the study design. Among the top 20 in silico synthesized compounds, as listed in Table II , diversified structures could be observed. Through the compound similarity search on the Scifinder, multiple patents were identified to contain compounds that have similar structural features with our in silico design. Series of compounds with reported mGluR allosteric activities were recurred in this case study for designing mGlu 5 allosteric modulators. The in silico designed compounds with reported scaffolds may fill SAR holes in the known, patented series of mGlu 5 modulators. And the recall of compounds with existing scaffolds and reported effects on mGluR showed that the approach we generated is feasible. Meanwhile, the generation of compounds without reported activities on mGluR indicates that our approach is doable for exploring and designing novel compounds. The medicinal chemistry synthesis for these in silico compounds is in progress in our laboratory, and we will perform the experiments to confirm our predictions in the future to find out whether they (1) are mGlu 5 allosteric modulators, (2) retain the ranking order the Fig. 8 . Structural comparison between in silico synthesized compounds and existing compounds with known mGluR allosteric activities. Comparisons were circled with dashed lines in red, blue, and pink colors. The major difference inside each group was circled with the same color as their group. The CAS number for patented compounds and the corresponding number for in silico synthesized compounds are listed under each structure same way as our prediction, and (3) have better activities than known modulators or not in a head-to-head comparison. Since the focus of this manuscript is more the methodology instead of the final products, the experimental validation is beyond the scope and will not be included. Our case study on designing allosteric modulators on mGlu5 suggested that this computational fragment-based approach is a reliable and powerful methodology for facilitating the future compound design processes.
